Toggle light / dark theme

AI model forecasts speech development in deaf children after cochlear implants

An AI model using deep transfer learning—the most advanced form of machine learning—has predicted spoken language outcomes with 92% accuracy from one to three years after patients received cochlear implants (implanted electronic hearing device).

The research is published in the journal JAMA Otolaryngology–Head & Neck Surgery.

Although cochlear implantation is the only effective treatment to improve hearing and enable spoken language for children with severe to profound hearing loss, spoken language development after early implantation is more variable in comparison to children born with typical hearing. If children who are likely to have more difficulty with spoken language are identified prior to implantation, intensified therapy can be offered earlier to improve their speech.

Modified tau thwarts aggregation in neurodegenerative disease—while retaining its biological function

A designer version of the tau protein, developed by a team led by UT Southwestern Medical Center researchers, maintains its biological function while resisting aggregation, a pathological trait linked to neurodegenerative diseases called tauopathies.

These findings, reported in Structure, could lead to new treatments for conditions including Alzheimer’s disease, frontotemporal dementia, chronic traumatic encephalopathy (CTE), and progressive supranuclear palsy.

“This is the first step toward creating a molecule that could, in principle, replace a protein that’s pathogenic (disease-causing) while still retaining its normal function,” said study leader Lukasz Joachimiak, Ph.D., Associate Professor in the Center for Alzheimer’s and Neurodegenerative Diseases and of Biochemistry and Biophysics at UT Southwestern.

New Brain Signal Predicts Alzheimer’s Years Before Diagnosis

Scientists at the Carney Institute for Brain Science have discovered specific patterns of electrical signals in the brain that may help forecast whether a person will go on to develop Alzheimer’s disease. Using a specialized tool designed to examine the electrical signals produced by neurons, sci

Prescriptions Rising for a New Non-Opioid Analgesic, but Clinicians Are Still Learning Where It Fits

Prescriptions for the new non-opioid pain medication suzetrigine more than doubled between April and August 2025, according to analysis from Epic Research. The increase indicates a growing interest in opioid alternatives for acute pain, even as clinicians grapple with how and where the drug best fits in practice.


Despite a surge in prescriptions for the non-opioid pain drug suzetrigine, clinicians are still sorting out who benefits the most and when.

Covenant Health says May data breach impacted nearly 478,000 patients

The Covenant Health organization has revised to nearly 500,000 the number of individuals affected by a data breach discovered last May.

The healthcare entity initially reported in July that the data of 7,864 people had been exposed, but further analysis has revealed a larger impact.

After completing “the bulk of its data analysis,” Covenant Health now says that 478,188 individuals were affected.

Amygdala Structure, Function, and Clinically Relevant Pathways

The amygdala consists of nuclei which can be grouped into (i) the basolateral nuclear group (BLA), (ii) the superficial cortex-like laminated region (sCLR) which contains the cortical nuclei (Co), and (iii) the centromedial nuclear group.1 The BLA consists of the lateral nucleus (LA) and basal nucleus (BA). In turn, the BA consists of the basolateral nucleus and the basomedial nucleus. The centromedial nuclear group consists of the central nucleus (Ce), medial nucleus (Me), and intercalate cell mass (IC). In turn, Ce consists of a lateral (CeL) subdivision and a medial (CeM) subdivision. The centromedial nuclear group (Ce, Me, and IC) along with the bed nucleus of the stria terminalis (BNST) and sublenticular substantia innominata together comprise the centromedial extended amygdala.

The cellular composition of the BLA nuclei and the sCLR’s Co nuclei resembles that of the cerebral cortex in that the majority of the neurons are pyramidal-like glutamatergic cells while the rest are local GABAergic inhibitory interneurons.1 The inhibitory interneurons include parvalbumin-containing neurons which mainly synapse on the soma and proximal dendrites of the pyramidal cells and somatostatin-containing neurons which mainly synapse on the distal dendrites of the pyramidal neurons. By contrast, the composition of the Ce and Me nuclei resembles the striatum in that many of the neurons are similar to GABAergic medium spiny neurons.

How do spinal cord injuries heal?

Investigators looked at laboratory mice with spinal cord injury and found that lesion-remote astrocytes (LRAs) play an important role in supporting nervous system repair. They saw strong evidence of the same mechanism in tissue samples from human patients with spinal cord injury.

The Lab identified one LRA subtype that sends out a protein called CCN1 to signal to immune cells called microglia.

“One function of microglia is to serve as chief garbage collectors in the central nervous system,” the senior author said. “After tissue damage, they eat up pieces of nerve fiber debris—which are very fatty and can cause them to get a kind of indigestion. Our experiments showed that astrocyte CCN1 signals the microglia to change their metabolism so they can better digest all that fat.”

The author said this efficient debris clearing might have a role in the spontaneous recovery found in many patients with spinal cord injury. In the absence of the astrocyte-derived CCN1 protein, the investigators found that recovery is drastically impaired.

“If we remove astrocyte CCN1, the microglia eat, but they don’t digest. They call in more microglia, which also eat but don’t digest,” the author said. “Big clusters of debris-filled microglia form, heightening inflammation up and down the spinal cord. And when that happens, the tissue doesn’t repair as well.”

When investigators looked at spinal cord tissue from human patients with multiple sclerosis, they found the same mechanism at work, the author said and added that these fundamental principles of tissue repair likely apply to any sort of injury of the brain or spinal cord.


We’ll learn about LSD’s potential for treating anxiety in 2026

Two major trials investigating the potential of the psychedelic drug LSD for reducing anxiety are set to conclude in 2026. Scientists are feeling positive after the drug’s success in an earlier-stage trial, which could mean the treatment will be available in the US as early as 2027.

Generalised anxiety disorder is a common condition where people feel very anxious about lots of different things. It is typically treated with antidepressants and talking therapies, but around half of people don’t respond to such treatments.

Other psychedelic drugs like psilocybin and MDMA are already used to treat particularly severe cases of depression and post-traumatic stress disorder in some countries, such as Australia and Switzerland. LSD is increasingly being explored as a mental health treatment, partly because research shows it triggers profound emotional experiences in some people, and it seems to enhance the brain’s ability to rewire itself and form new thought patterns.

Image: TUMEGGY/SCIENCE PHOTO LIBRARY/GETTY IMAGES


Two later-stage trials investigating LSD for treating anxiety are due to conclude in 2026, which could lead to the drug being approved for the common mental health condition.

By Carissa Wong

/* */